$1.64
10.07% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Editas Medicine, Inc. Stock price

$1.64
+0.31 23.31% 1M
-0.77 31.95% 6M
+0.37 29.13% YTD
-3.88 70.29% 1Y
-9.38 85.12% 3Y
-26.92 94.26% 5Y
-16.56 90.99% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.15 10.07%
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Key metrics

Market capitalization $137.29m
Enterprise Value $-52.54m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.24
EV/Sales (TTM) EV/Sales -1.47
P/S ratio (TTM) P/S ratio 3.83
P/B ratio (TTM) P/B ratio 2.20
Revenue growth (TTM) Revenue growth -48.37%
Revenue (TTM) Revenue $35.84m
EBIT (operating result TTM) EBIT $-207.24m
Free Cash Flow (TTM) Free Cash Flow $-215.28m
Cash position $220.96m
EPS (TTM) EPS $-3.04
P/E forward negative
P/S forward 8.75
EV/Sales forward negative
Short interest 13.91%
Show more

Is Editas Medicine, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Editas Medicine, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Editas Medicine, Inc. forecast:

6x Buy
38%
8x Hold
50%
2x Sell
13%

Analyst Opinions

16 Analysts have issued a Editas Medicine, Inc. forecast:

Buy
38%
Hold
50%
Sell
13%

Financial data from Editas Medicine, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
36 36
48% 48%
100%
- Direct Costs 6.32 6.32
7% 7%
18%
30 30
53% 53%
82%
- Selling and Administrative Expenses 60 60
1% 1%
167%
- Research and Development Expense 171 171
7% 7%
476%
-201 -201
12% 12%
-561%
- Depreciation and Amortization 6.32 6.32
7% 7%
18%
EBIT (Operating Income) EBIT -207 -207
12% 12%
-578%
Net Profit -251 -251
51% 51%
-701%

In millions USD.

Don't miss a Thing! We will send you all news about Editas Medicine, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Editas Medicine, Inc. Stock News

Positive
Seeking Alpha
about 18 hours ago
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.
Positive
The Motley Fool
5 days ago
Explore the exciting world of Editas Medicine (EDIT 1.09%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Neutral
Seeking Alpha
6 days ago
Editas Medicine, Inc. (NASDAQ:EDIT ) BofA Securities 2025 Healthcare Conference May 14, 2025 8:15 PM ET Company Participants Amy Parison - CFO Christi Bernett - SVP of IR Conference Call Participants Alec Stranahan - BofA Securities Alec Stranahan Welcome to the last fireside for day 1 of the 2025 Bank of America Healthcare Conference. Thanks for joining this session with Editas.
More Editas Medicine, Inc. News

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Gilmore O’Neill
Employees 246
Founded 2013
Website www.editasmedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today